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Introduction: Only 3 to 5% of new adult cancer patients participate
in clinical trials nationwide. The lack of knowledge and awareness
about clinical trials is a significant barrier to clinical trials participation.
A randomized trial was conducted to test the effect of an educational
video on positively changing patients’ knowledge and attitudes regard-
ing clinical trials and thereby increasing enrollment rates.
Methods: Lung cancer patients were randomized to viewing either
an 18-minute video about clinical trials before first clinic appoint-
ment or to standard care. Participants completed a baseline and
2-week postintervention survey to assess their knowledge and atti-
tudes toward trials participation. Fisher’s exact test tests, t tests, and
regression were used to compare patient characteristics and out-
comes between arms.
Results: Of 145 subjects randomized, 126 (63/arm) satisfied all
inclusion criteria and were included in the analysis. A linear regres-
sion showed that the video intervention was significantly associated
with patients’ self-assessed likelihood to enroll score measured at
2-week follow-up (p  0.019). Although statistically insignificant,
enrollment rates were found to be higher in the intervention arm for
therapeutic trials alone (17.5% versus 11.1%) and for therapeutic
and nontherapeutic trials combined (25.4% versus 15.9%).
Conclusions: The brief educational video seems to be effective in
positively changing lung cancer patients’ attitudes about participa-
tion in clinical trials. Higher enrollment rates were also observed in
the intervention group but the differences did not reach statistical
significance. These findings suggest a potential impact of the edu-
cational video on clinical trial enrollment; however, larger studies
are needed to confirm these findings.
Key Words: Clinical trail enrollment, Lung cancer, Educational
intervention, Video.
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Most major clinical advancements in cancer therapeuticscome from clinical trials, which are essential for im-
proving patient outcomes. Clinical trials offer cancer patients
access to innovative therapeutic options frequently associated
with better treatment outcomes.1–4 However, despite the large
number of available studies, only an estimated 3 to 5% of all
newly diagnosed cancer patients participate in clinical trials
nationwide.5,6 Low participation in clinical trials lengthens a
trial’s duration and delays the delivery of potentially life-
saving treatments to cancer patients. In addition, lower par-
ticipation rate among African Americans7–10 (AAs) limits the
generalizability of the findings. To speed treatment advance-
ments and ensure that trial results are valid across all racial
groups, new strategies are needed to increase participation
and diversity in clinical trials.
Barriers to clinical trials participation can be attributed
to various sources including factors related to the physician,
patient, specific trial enrollment criteria, and costs.8,11–15
Several studies have documented that lack of information
about clinical trials is a significant barrier to trial enroll-
ment.10,16,17 Fears based on awareness of historical abuses of
human subjects’ rights in biomedical research also seem to be
barriers, particularly in AA populations.18,19 However, lim-
ited research has described or tested new strategies to over-
come clinical trial enrollment barriers.
Not only are there misconceptions about clinical trials,
most cancer patients simply do not have much knowledge
regarding clinical research. Pinto et al.17 found that lack of
information was the most significant barrier to recruiting minor-
ity participants to cancer clinical trials, and suggested the need to
educate patients to overcome these common barriers. A survey
of 6000 cancer patients conducted by Harris Interactive5 (Roch-
ester, NY) found that 85% were either unaware or unsure that
participation in clinical trials was an option. Among the 15%
who were aware of clinical trials, three of four refused to
participate. The most common reasons were: (1) belief they
would be better off getting standard treatment, (2) fear they
might get a placebo, (3) fear they would be a “guinea pig,” and
(4) concerns about insurance not covering trial costs.
The few studies testing new educational interventions
as a tool to increase trials enrollment yielded mixed re-
sults.20–22 One study evaluated the impact of an educational
booklet on women’s knowledge and willingness to participate
in randomized breast cancer clinical trials, and found that the
booklet was ineffective in improving trial enrollment.20 An-
other study investigated the effect of an educational interven-
tion on potential participants of a randomized clinical trial for
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men with early-stage prostate cancer.21 The 90-minute inter-
vention included an informed consent video and seminars led
by a former trial participant, urologist, and radiation oncolo-
gist. The study participants responded favorably to the edu-
cational intervention with the resulting enrollment rate of
12% (32 of 263). However, because of the lack of a control
group, it is difficult to interpret these results. The third study,
which tested an intervention to increase the enrollment of a
large sample of older cancer patients onto cooperative trials,
randomly assigned member institutions of the Cancer and
Leukemia Group B to standard information versus an educa-
tional intervention. Standard information included Web site
access and periodic notification about existing trials. The
educational intervention included the standard information
plus two seminars and additional educational materials
through e-mail during a 1-year period. No difference in
accrual was found between the study arms.22
The National Cancer Institute (NCI) recently developed
a patient education series on cancer clinical trials, including a
video titled Cancer Clinical Trials: An Introduction for
Patients and their Families. This patient education video is
an inexpensive and easy way for health professionals to
increase patient and family awareness, and to spark discus-
sion about cancer clinical trials. It presents a view on clinical
trials from the perspectives of patients with diverse ethnic
backgrounds and characteristics. The current study is among
the first to test the efficacy of this educational video on
increasing enrollment onto cancer clinical trials. The aim of
this study was to determine whether the use of this video in
a Multidisciplinary Lung Clinic (MDL) at a large compre-
hensive cancer center would positively change patients’
knowledge and attitudes regarding clinical trials and thereby
improve clinical trial enrollment. Based on Andersen’s23,24
health behavior model, it was hypothesized that pretreatment
patient education would achieve these aims.
MATERIALS AND METHODS
Study Design
This randomized, two-arm study examined the effects
of a brief educational intervention, i.e., a NCI-developed
video, on clinical trial enrollment among patients with lung
cancer. Participants were randomized to either standard care,
i.e., their first visit with a medical oncologist, or to the
intervention before standard care. All aspects of the study
were approved by Wayne State University Human Investiga-
tions Committee.
Sample Size and Randomization
The sample size and power calculations were based on
the primary attitudinal end point which measures patients’
self-assessed likelihood to enroll in a clinical trial, measured
on 1 to 5 scale. To detect a difference of 0.5 point between the
two study arms, 63 eligible patients in each arm were needed,
assuming a standard error of 1, 80% power, and 5% type I
error (two-sided test). However, because of difficulties in
verifying patients’ eligibility for this study before random-
ization, we estimated 150 patients (20% oversampling) would
be required to achieve our accrual goal. The same sample size
would allow us to test the hypothesis that the video interven-
tion would increase clinical trial enrollment by at least 20%
(10% versus 30%) with 80% power and 5% type I error. A
restricted block randomization method (block size of 6) was
used to achieve balanced accrual between study arms. Ran-
domization was stratified by race (AA or white) and the four
treating oncologists.
Inclusion Criteria
Participants were patients scheduled for evaluation by a
medical oncology specialist between September 2003 and
April 2005 at the MDL at Karmanos Cancer Institute (KCI)
in Detroit, MI. KCI is one of 55 NCI-designated comprehen-
sive cancer centers in the United States. Patients aged 21 to
80 years were eligible for this study if they were new to the
MDL clinic, had a diagnosis of histologically confirmed
invasive lung cancer, and were self-identified as either AA or
white. AA patients comprised approximately 36% of our total
lung cancer population from 2003 to 2005. Patients of other
races represent 1% of our patient population and thus were
not included in this study. Other inclusion criteria were:
a. Ability to read and understand English at least at the 6th
grade level,
b. Capable of making decisions regarding their own treat-
ment,
c. Not having previously participated in a clinical trial, and
d. Performance status (PS) 2 (Southwest Oncology
Group scale).
Video Intervention
The 18-minute NCI video titled Cancer Clinical Trials:
An Introduction for Patients and their Families selected for
this study presents an overview of phase I, II, and III clinical
trials and the importance of cancer clinical research to soci-
ety. From diverse patients’ perspectives, the video addresses
common concerns regarding clinical trials and cancer treat-
ment such as side effects, expected risks and benefits, eligi-
bility criteria, the enrollment process, and treatment costs.
Patients are informed how the randomization process works
and assured that, because placebo treatments are rarely used
in therapeutic cancer clinical trials, they would receive noth-
ing less than the best available standard therapy if they decide
to participate in a clinical trial. The video also emphasizes
that patients are always provided all the facts about the study
treatment through the “informed consent” process before
enrollment. Patients are told that they can withdraw from a
trial at any time, and that clinical trials are monitored and
reviewed routinely by an Institutional Review Board and a Data
and Safety Monitoring Committee. Because it addressed known
barriers to trial participation, and because the patients in the
video mirrored the cultural diversity seen in MDLs patient
population, this video was judged to be appropriate to meet the
aims of this study. More information about the video can be
found on the NCI educational website (http://www.cancer.gov/
clinicaltrials/learning/clinical-trials-education-series).
Study Procedures
Patients were contacted by phone about participating in
this study by the Study Coordinator before their first MDL
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appointment. Consenting participants met with the Study
Coordinator 1 hour before their scheduled appointment to
provide written informed consent, baseline demographics,
and to complete a questionnaire (pretest) measuring their
knowledge and attitudes about clinical trials. Upon comple-
tion of the questionnaire, study participants were randomized
to either the control or intervention arm. Participants random-
ized to the intervention arm proceeded to view the video,
whereas those in the control arm returned to the waiting room
for their clinic appointment. Participants then met with their
oncologist, who was unaware of their patients’ participation
or randomization in the study. Two weeks after the first
appointment, the same questionnaire was mailed to all par-
ticipants to reassess their knowledge and attitudes about
clinical trials (posttest). A medical oncologist or physician
assistant completed a treatment notification form after the
participants’ follow-up visit to verify clinical trial eligibility
and their subsequent enrollment decision.
Survey Instruments
A one-page self-administered questionnaire was used to
measure participant knowledge and attitudes about clinical
trials before and after intervention. This knowledge/attitudes
questionnaire consisted of one question assessing the likeli-
hood that the participant would enroll in a clinical trial, as
well as 15 other questions in three subscales. The single item
simply asked patients the following question “At this mo-
ment, how likely do you think you are to agree to participate
in a clinical trial if one was offered to you? 1–Extremely
unlikely, 2–unlikely, 3–don’t know, 4–likely, 5–extremely
likely.” This item directly assesses patients’ general attitudes
about clinical trial participation. It also indirectly assesses
patients’ willingness to participate in a clinical trial. The
remaining 15 items, taken from a survey developed by Mich-
igan State University (MSU) researchers, Drs. Barbara and
Charles Givens, comprised subscales measured patients’ al-
truism, perceived personal benefits, and perceived negative
aspects related to participation in clinical trials. All questions
in the survey were scored on a five-point scale, and each of
the three subscales was standardized into scores of 0 to 100.
The “notification of treatment decision form” com-
pleted by the oncologist or physician assistant recorded each
patient’s stage of disease, cancer histology, Southwest On-
cology Group PS, the presence of comorbidities, and whether
or not the participant enrolled onto a clinical trial. Comorbid
conditions evaluated included diabetes, heart disease, chronic
lung disease, liver disease, and renal disease.
A baseline demographic data form was used to collect
participants’ gender, race, age, marital status, education,
employment status, occupation, and socioeconomic status
(SES) at the time of the pretest. The SES variable used
Hollingshead’s 4-factor scoring system25 incorporating both
participant and spouse education and occupation (single pa-
tients used only their own information) to categorize partic-
ipants as low, medium, or high SES.
All instruments used in this study were reviewed by
study consultants and KCI behavioral scientists for content
validity, and pilot tested in a sample of 10 cancer patients,
selected on the same criteria as study participants, to evaluate
clarity, level of understanding, and acceptability for use in
this prospective approach.
Study Outcomes
The primary outcome variables included the one-item
scale measuring the participant’s self-assessed likelihood to
enroll in a clinical trial, the enrollment rate onto therapeutic
trials, and the enrollment rate onto therapeutic and nonthera-
peutic clinical trials combined (i.e., educational, behavioral,
chemoprevention, and tissue collection studies). Clinical tri-
als enrollment data, excluding the current study, were derived
from physicians’ responses on the treatment notification form
and later confirmed by the KCI Clinical Trials Office data-
base. Other study outcomes included the three composite
knowledge/attitude subscales measuring altruism, perceived
personal benefits, and perceived negative aspects related to
clinical trial participation.
Statistical Methods
Two-sample t tests and Fisher’s exact test tests were
used to assess differences in patient characteristics and study
outcomes between study arms. Linear and logistic regression
analyses were used to assess differences in outcomes between
arms while controlling for covariates. The -level for signif-
icance was set at 0.05, and all reported p values are based on
two-sided tests.
RESULTS
A total of 149 patients were contacted, four refused to
participate in the study (2.7%), and the remaining 145 had
completed the baseline survey and received the study ran-
domization. Because of the difficulties in determining patient
eligibility before randomization, some participants, once seen
by their oncologists, were determined to be ineligible and
dropped from the study. After excluding patients with poor
PS (PS 2) (n  10), advanced age (80) (n  1), a wrong
cancer diagnosis or missing stage (n  7), and those who
were lost to follow-up (n  1), 126 (86.9%) eligible patients,
with 63 patients in each arm, were available for analysis
(Figure 1).
Table 1 compares the participants’ demographics by
study arm. Mean and median age of the participants was 58.5
and 58.7 years. Among the participants, 29% were AA, 46%
were women, and 50% scored in the “low” SES category.
There were no significant differences by treatment arm on
any of the demographic variables.
Table 2 compares the participants’ clinical characteris-
tics by study arm. The majority of participants (84%) had
non-small cell lung cancer, whereas 16% had small cell lung
cancer. By eligibility criterion, all participants had a PS 2.
Among the 126 participants, 31% had PS 0; 49% had PS
1; 20% had PS  2. One or more comorbid conditions were
reported by 28% of participants. There were no significant
differences between study arms in regards to stage, histology,
PS, or comorbidity.
Table 3 compares participants’ self-assessed likelihood
to enroll score, clinical trial enrollment rates, and the three
knowledge/attitude composite subscale scores by study arm.
At baseline, 19% of participants in both arms responded
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“extremely likely” when asked how likely they were to
participate in a future clinical trial. At 2-week follow-up, 39%
in the intervention arm as compared with 22% in the control
arm (p  0.035) responded “extremely likely” when asked
the same question. When examining the raw score of the
self-assessed likelihood to enroll scale, the mean scores were
identical at baseline for the two arms (3.51  1.03 versus
3.54  1.04; p  0.864), whereas at 2-week follow-up, the
intervention group had a significantly higher score than the
controls (3.75  1.26 versus 3.28  1.32; p  0.047).
Furthermore, when examining the change in score from
baseline to follow-up, there was an even more significant
difference with the intervention arm having a greater increase
in their self-assessed likelihood to enroll score as compared
with controls (0.28  0.99 versus 0.27  1.27; p  0.010).
Table 3 also shows that clinical trial enrollment rates were
higher for participants in the intervention arm for therapeutic
trials alone (17.5% versus 11.1%; p  0.308), and for both
therapeutic and nontherapeutic trials combined (25.4% versus
15.9%; p  0.187), although these differences are not statis-
tically significant at   0.05 level.
When comparing the three subscales measuring altru-
ism, perceived personal benefits, and perceived negative
aspects, no differences between study arms were found at
baseline or follow-up. There were also no differences in the
change scores for these subscales by study arms.
To assess the association of the four knowledge/atti-
tudes scales (likelihood score and three attitudinal subscales)
with clinical trials enrollment, two-sample t tests were used to
see if patients who chose to participate in clinical trials scored
statistically different at time of follow-up than those who
chose not to participate. Analysis results showed that likeli-
hood to enroll score at follow-up was significantly positively
correlated with actual enrollment onto therapeutic trials (p 
0.007) and onto all types of trials (p  0.05). Among the
three subscales, only perceived negative aspects was corre-
lated with enrollment onto therapeutic trials (p  0.04).
Altruism and perceived personal benefits were not correlated
with trial enrollment.
Table 4 shows the results of a linear regression analysis
on the change in likelihood to enroll score. This analysis
shows that after adjusting for all other covariates, the video
intervention continues to show a significant positive impact
on changing participant’s attitudes in terms of their self-
assessed likelihood to enroll (  0.50; p  0.019). None of
the covariates including age, gender, race, SES rank, marital
status, education, or the presence of comorbid medical con-
ditions were correlated with the change in the likelihood to
enroll score.
Logistic regression analyses were conducted to assess
differences in trial enrollment rates between arms while
controlling for the same covariates. Neither the study inter-
vention nor other patient factors was shown to be signifi-
cantly correlated with trial enrollment.
DISCUSSION
Several studies have found that lack of information is a
significant barrier to clinical trials participation.16,17 Another
Harris Interactive survey on cancer patients26 showed that
81% of the respondents were not aware of safeguards such as
the Declaration of Helsinki, Institutional Review Boards, or
the informed consent process. Fouad et al. cited findings from
TABLE 1. Sociodemographic Characteristics of Participants
Characteristics
All Patients
(n  126)
Intervention
(n  63)
Control
(n  63)
p
(Two-sided)
African American (%) 29 27 30 0.693
Male (%) 51 49 52 0.593
Age (median/mean) 58.7/58.5 58.0/58.2 59.8/58.7 0.719
Married (%) 65 68 62 0.495
Employed (%) 31 33 30 0.753
SES ranking (%)a 0.737
High 20 23 17
Medium 30 27 32
Low 50 50 51
a The scoring of the SES variable utilized Hollingshead’s 4-factor scoring system.25
4 refused
145 patients consented 
to participate and completed 
baseline assessment
73 assigned to 
intervention 
72 assigned to 
control arm
10 ineligible 9 ineligible
63 completed 
follow-up survey
63 completed 
follow-up survey
149 patients invited
 to participate in study
Randomization
FIGURE 1. A flow chart of the progress of study partici-
pants from the time of initial contact until the end of their
involvement.
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focus groups that the majority of patients were unclear
regarding the nature of clinical trials.16 These studies further
highlight the need to educate cancer patients about clinical
trials to increase enrollment. In addition, several studies that
evaluated the effects of various educational interventions on
clinical trials participation20–22 reported disappointing results.
We conducted a two-arm randomized study to evaluate
the efficacy of an 18-minute educational video to improve
participation in clinical trials among lung cancer patients at a
large comprehensive medical center. Unlike the two studies
described earlier,21,22 which involved rather intensive inter-
ventions, our format of patient education has the potential to
have universal applicability given its low demand on staff and
patient time and ease and low cost of administration. Our data
show that the educational intervention had a statistically
significant impact on patients’ attitudes toward clinical trial
participation with or without adjustment of covariates. A few
observations that further strengthen this finding are (1) the
likelihood to enroll score was identical for the two arms at
baseline, (2) no other patient-level factors were associated
with the change in likelihood to enroll, and (3) the likelihood
to enroll score was significantly correlated with actual trial
TABLE 2. Clinical Characteristics of Participants
Characteristics
All Patients
(n  126)
Intervention
(n  63)
Control
(n  63)
p
(Two-sided)
Stage/histology (%)a 0.869
NSCL
Stage I 10 10 10
Stage II 4 3 5
Stage III 25 29 22
Stage IV 45 41 49
SCL
Limited 6 8 3
Extensive 10 9 11
Performance status (%)b 0.484
0 31 30 32
1 49 53 43
2 20 17 25
Comorbidity (yes vs. no)c 28 29 27 0.915
a NSCL (non-small cell lung cancer), SCL (small cell lung cancer).
b South West Oncology Group (SWOG) performance status ranking.
c Comorbid conditions examined include diabetes, chronic obstructive pulmonary disease (COPD), heart disease, renal
disease, and liver disease.
TABLE 3. Comparison of Study Outcomes by Study Arms
Outcomes
Intervention
(n  63)
Control
(n  63)
p
(Two-sided)
Likelihood to enroll score—baseline 3.51  1.03a 3.54  1.0a 0.864
Responded “extremely likely” (%) 19 19 1.000
Likelihood to enroll score—follow-up 3.75  1.26 3.28  1.32 0.047b
Responded “extremely likely” (%) 39 22 0.035b
Enrollment in therapeutic trials (%) 17.5 11.1 0.308
Enrollment in therapeutic/nontherapeutic trials (%) 25.4 15.9 0.187
Change in likelihood to enroll score 0.28  0.99 0.27  1.27 0.010c
Baselined
Altruism 71.4  27.8 72.0  27.2 0.914
Personal benefits 87.7  14.8 85.3  17.5 0.406
Negative aspects 65.7  29.6 62.6  26.2 0.545
Two-week follow-up
Altruism 70.8  28.1 67.2  24.8 0.463
Personal benefits 83.2  17.7 81.1  18.3 0.526
Negative aspects 57.3  23.2 59.9  22.7 0.546
a Mean  standard deviation.
b p  0.05.
c p  0.01.
d Subscales were standardized into scores of 0–100.
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enrollment, suggesting the validity of using this single-item
scale to measure the impact of the video intervention. Our
data also indicate that although clinical trials enrollment rates
were not statistically different between the two arms of the
study, enrollment onto therapeutic trials (17.5% versus
11.1%) and onto therapeutic/nontherapeutic trials combined
(25.4% versus 15.9%) were both higher for participants
assigned to the video intervention. Although modest, an
increase in clinical trials enrollment by 6.4% for therapeutic
trials and 9.5% for any type of clinical trials could have potential
clinical significance nationally and internationally because of the
low cost and ease of implementation of the video intervention.
Larger studies are needed to confirm the effect of this educa-
tional intervention on clinical trial enrollment.
As for the possible reasons why the significant change
in patients’ attitudes in terms of their likelihood to enroll was
not followed by a significant increase in actual trial enroll-
ment, it was likely because of the fact that many other factors
also contribute to low trial enrollment.8,11–15 For example, strin-
gent trial eligibility criteria or not enough open trials to accom-
modate patients of all stages are common barriers contributing to
low enrollment. Patient education is only the first step toward
increasing clinical trials enrollment rate. Effort toward removing
nonpatient-level barriers is needed to achieve significant in-
crease in clinical trial enrollment rate nationally.
A major weakness of this pilot study is its relatively
small sample size. The prestudy power analysis was based on
the one-item attitudinal score. A pilot study of this size does
not have sufficient statistical power to detect a difference in
enrollment rate between arms that is less than 20%. Another
weakness is that study participants’ eligibility to therapeutic
clinical trials available at the time of their treatment was not
collected. Analyses comparing the enrollment in therapeutic
trials between the two study arms would have been more
meaningful if restricted to only eligible patients. In addition,
unlike the likelihood score, the three knowledge/attitude
subscales correlated poorly with patients’ trial enrollment.
This was likely because of the fact that these three subscales
were not designed to measure longitudinal changes in knowl-
edge/attitudes, despite their prestudy face validity. An instru-
ment directly measuring aspects of patient knowledge and
attitudes that are specifically targeted in the video could be
more sensitive to measure change in future studies. Lastly
because only lung cancer patients were included in this study,
generalization of the study results to other types of cancer
should be done with caution.
In summary, the NCI educational video seems to be
an effective educational tool for positively changing lung
cancer patients’ attitudes toward participation in clinical
trials. Although the higher enrollment rates in the inter-
vention arm are encouraging, larger studies are needed to
further examine the effect of this video on actual clinical
trial enrollment. If the differences in enrollment rates
found in this study are validated, this format of patient
education would be easy and cost-efficient to integrate into
current clinical practice.
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